EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
July 27 2022 - 7:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical
company committed to developing and commercializing therapeutics to
improve the lives of patients with serious eye disorders, today
announced it will host a conference call and live webcast at 8:30
a.m. ET on Wednesday, August 3, 2022 to report its second quarter
2022 financial results and highlight recent corporate developments.
To access the live conference call, please
register using the audio conference link:
https://register.vevent.com/. A live audio webcast of the event can
be accessed via the Investors section of the Company website at
www.eyepointpharma.com. A webcast replay will also be available on
the corporate website at the conclusion of the call.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
pharmaceutical company committed to developing and commercializing
therapeutics to help improve the lives of patients with serious eye
disorders. The Company's pipeline leverages its proprietary
Durasert® technology for sustained intraocular drug delivery
including EYP-1901, an investigational sustained delivery
intravitreal anti-VEGF treatment initially targeting wet
age-related macular degeneration. The proven Durasert drug delivery
platform has been safely administered to thousands of patients'
eyes across four U.S. FDA approved products, including YUTIQ® for
the treatment of chronic non-infectious uveitis affecting the
posterior segment of the eye, which is currently marketed by the
Company. EyePoint Pharmaceuticals is headquartered in Watertown,
Massachusetts.
Investors:
Christina TartagliaStern IRDirect:
(212)-698-8700christina.tartaglia@sternir.com
Media Contact
Amy PhillipsGreen Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024